The 340B rebate pilot model set to begin in January 2026 starkly presents the key tradeoff between program integrity and ...

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

For more than 30 years, thanks to bipartisan congressional support, the 340B program has helped eligible hospitals stretch limited federal resources to reduce the price of outpatient pharmaceuticals ...

Learn what the HHS 340B Drug Pricing Program is and what 340B hospitals are. The program allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals ...

When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...

A late 2021 survey of hospitals participating in the 340B drug pricing program suggests pharma industry leaders’ recent restrictions on drug discounts are costing safety net hospitals hundreds of ...

Senate HELP Committee Hearing Highlights Urgent Need to Reform 340B Program — Lawmakers Push for Transparency and Patient ...

Can ambulatory pharmacy drive growth? Healthcare leaders share strategies to optimize pharmacy models amid policy and market shifts.

Oregon Health & Science University leaders say a federal drug discount pilot set to begin next year could create a “significant cash-flow risk” for the institution and undermine its ability to serve ...

The 340B program presents covered entities with very important financial support to assist with the extension of care to the most vulnerable populations. However, the program is under scrutiny from ...

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...

Using the ruse of “price negotiation”, the proponents of the Build Back Better legislation are pushing an ill-fated drug price control plan. Patients will bear exceptionally large costs should their ...